HedgeChatter

  • Home /
  • Tag Archives

WX

WuXi PharmaTech Completes Construction of New Materials Characterization Facility in St. Paul

[PR Newswire] – SHANGHAI, May 12, 2014 /PRNewswire/ — WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United … moreView todays social media effects on WXView the latest stocks trending across Twitter. Click to view dashboardSee who WuXi is hiring next, click here to view […]

May 12, 2014 Bystocknews , Comments Off on WuXi PharmaTech Completes Construction of New Materials Characterization Facility in St. Paul read more

FDA Approves Ibalizumab Manufactured by WuXi PharmaTech for Treatment of Patients on Expanded Access

[PR Newswire] – SHANGHAI and TAIPEI, May 5, 2014 /PRNewswire/ — WuXi PharmaTech (NYSE: WX) and TaiMed Biologics today announced that the FDA has approved the first batch of the ibalizumab (TMB-355) drug substance and … moreView todays social media effects on WXView the latest stocks trending across Twitter. Click to view dashboardSee who WuXi is hiring next, click here […]

May 5, 2014 Bystocknews , Comments Off on FDA Approves Ibalizumab Manufactured by WuXi PharmaTech for Treatment of Patients on Expanded Access read more

WUXI PHARMATECH (CAYMAN) INC. Financials

moreView todays social media effects on WXView the latest stocks trending across Twitter. Click to view dashboardSee who WuXi is hiring next, click here to view […]

April 18, 2014 Bystocknews , Comments Off on WUXI PHARMATECH (CAYMAN) INC. Financials read more

4:33 pm WuXi PharmaTech beats by $0.07, reports revs in-line; guides Q1 EPS below consensus, revs below consensus; guides FY14 EPS above consensus, revs in-line

moreView todays social media effects on WXView the latest stocks trending across Twitter. Click to view dashboardSee who WuXi is hiring next, click here to view […]

March 6, 2014 Bystocknews , Comments Off on 4:33 pm WuXi PharmaTech beats by $0.07, reports revs in-line; guides Q1 EPS below consensus, revs below consensus; guides FY14 EPS above consensus, revs in-line read more